Home    Back

Esketamine    (DrugBank: Esketamine)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
4Primary lateral sclerosis1
70Spinal stenosis0

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-000142-18-FI
(EUCTR)		09/05/201808/05/2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Amyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Trade Name: Ketanest-S
INN or Proposed INN: ESKETAMINE		Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 4Finland

4. Primary lateral sclerosis    [ 6 clinical trials,   16 drugs,   (DrugBank: 8 drugs),   19 drug target genes,   32 drug target pathways]
Searched query = "Primary lateral sclerosis", "PLS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 6 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-000142-18-FI
(EUCTR)		09/05/201808/05/2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Amyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Trade Name: Ketanest-S
INN or Proposed INN: ESKETAMINE		Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 4Finland

70. Spinal stenosis    [ 91 clinical trials,   195 drugs,   (DrugBank: 54 drugs),   60 drug target genes,   85 drug target pathways]
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 91 trial found